Share on StockTwits

Shares of Hemispherx BioPharma, (NYSE:HEB) were the recipient of a significant decline in short interest during the month of August. As of August 15th, there was short interest totalling 1,072,995 shares, a decline of 5.6% from the July 31st total of 1,136,132 shares, Analyst Ratings Network reports. Approximately 0.6% of the shares of the stock are sold short. Based on an average daily trading volume, of 468,969 shares, the days-to-cover ratio is currently 2.3 days.

Shares of Hemispherx BioPharma, (NYSE:HEB) opened at 0.2725 on Thursday. Hemispherx BioPharma, has a 1-year low of $0.19 and a 1-year high of $0.55. The stock’s 50-day moving average is $0. and its 200-day moving average is $0.33. The company’s market cap is $51.8 million.

Hemispherx Biopharma, Inc (NYSE:HEB) is a specialty pharmaceutical engaged in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders.

Receive News & Ratings for Hemispherx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma and related companies with Analyst Ratings Network's FREE daily email newsletter.